# Epigenetic Silencing of ZNF471 Contributes to Osimertinib Resistance in Lung Adenocarcinoma: β-Hydroxybutyrate Associates with ZNF471 Re-Expression and Reduced Resistance-Associated Phenotypes

_Oncology Research · Dade Feng, Huiting Yan, Qian Ni et al. · 2026_

Canonical: https://diginpl.com/books/paper-or-2026-087712
Last updated: 2026-10-23

## Quick facts

- **Author:** Dade Feng; Huiting Yan; Qian Ni; Zirui Peng; Xiong Xu; Yanfang Liang; Chongmei Liu ([Crossref](https://doi.org/10.32604/or.2026.087712))
- **Published:** 2026 ([Crossref](https://doi.org/10.32604/or.2026.087712))
- **Publisher:** Tech Science Press ([Crossref](https://doi.org/10.32604/or.2026.087712))
- **Journal:** Oncology Research ([Crossref](https://doi.org/10.32604/or.2026.087712))
- **DOI:** 10.32604/or.2026.087712 ([Crossref](https://doi.org/10.32604/or.2026.087712))

## Questions

**Who wrote Epigenetic Silencing of ZNF471 Contributes to Osimertinib Resistance in Lung Adenocarcinoma: β-Hydroxybutyrate Associates with ZNF471 Re-Expression and Reduced Resistance-Associated Phenotypes?**  
Epigenetic Silencing of ZNF471 Contributes to Osimertinib Resistance in Lung Adenocarcinoma: β-Hydroxybutyrate Associates with ZNF471 Re-Expression and Reduced Resistance-Associated Phenotypes was written by Dade Feng, Huiting Yan, Qian Ni, Zirui Peng.

**When was Epigenetic Silencing of ZNF471 Contributes to Osimertinib Resistance in Lung Adenocarcinoma: β-Hydroxybutyrate Associates with ZNF471 Re-Expression and Reduced Resistance-Associated Phenotypes first published?**  
Epigenetic Silencing of ZNF471 Contributes to Osimertinib Resistance in Lung Adenocarcinoma: β-Hydroxybutyrate Associates with ZNF471 Re-Expression and Reduced Resistance-Associated Phenotypes was first published in 2026.

## Sources

- [Publisher record (DOI, via Crossref)](https://doi.org/10.32604/or.2026.087712)

## Licence and attribution

Open-access publication. Read it free at the publisher: https://doi.org/10.32604/or.2026.087712.

## Cite this page

"Epigenetic Silencing of ZNF471 Contributes to Osimertinib Resistance in Lung Adenocarcinoma: β-Hydroxybutyrate Associates with ZNF471 Re-Expression and Reduced Resistance-Associated Phenotypes". DigiNepal. Last updated 23 October 2026. https://diginpl.com/books/paper-or-2026-087712. Retrieved 14 November 2026.